Effect of SGLT2 inhibitor on energy metabolism in patients with type 2 diabetes

Effect of SGLT2 inhibitor on energy metabolism in patients with type 2 diabetes - Effect of SGLT2 inhibitor on energy metabolism in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024822

Enrollment

100

Registered

2017-01-01

Start date

2017-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

SGLT2 innhibitor: once-daily SGLT2 inhibitor (dapagliflozin 5mg) as add-on to the conventional treatment for 1 week. Low-carbo diet: low-carbo (40-45%) diet as add-on to the conventional treatment for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion Criteria are type 2 diabetes, age between 20 and 80 years, and BMI>20

Exclusion criteria

Exclusion criteria: Exclusion criteria are type 1 diabetes, secondary diabetes, severe ketosis, diabetic coma or pre-coma patients, alcoholism, severe depression or other psychological condition, malignancy, viral hepatitis, severe liver dysfunction, abnormal hemoglobinemia, severe infections diseases, pre- or post-surger, severe traumatic injury, contraindication for MRI like having metal pieces embedded in the body, pregnant or lactating woman, renal deficiency(eGFR<45mL/min/1.73m2), history of hypersensitivity to dapagliflozin, and those who are not considered to be suitable by an attending physician.

Design outcomes

Primary

Measure	Time frame
Changes in hepatocellular adenosine triphosphate (ATP) concentrations from baseline	—

Countries

Japan

Contacts

Public ContactHospital Kyoto University Hospital

General Affairs Division Research Promotion Unit

trans@kuhp.kyoto-u.ac.jp075-751-4899

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026